Neuronal acetylcholine receptor; alpha4/beta2 · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Neuronal acetylcholine receptor; alpha4/beta2 shows approved-linked disease relevance led by nicotine dependence. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P17787. Start with nicotine dependence, then reuse UniProt P17787 as the stable protein anchor across project notes and exports.
Start with nicotine dependence, then reuse UniProt P17787 as the stable protein anchor across project notes and exports.
Neuronal acetylcholine receptor; alpha4/beta2 shows approved-linked disease relevance led by nicotine dependence. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.
Start review with nicotine dependence because it currently carries approved-linked support. Linked drugs include CYTISINICLINE, DIANICLINE, NICOTINE, NICOTINE POLACRILEX. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyNeuronal acetylcholine receptor subunit beta-2
Review this target as Neuronal acetylcholine receptor; alpha4/beta2, mapped to UniProt P17787. ChEMBL maps the protein component as Neuronal acetylcholine receptor subunit beta-2. Sequence length is 502 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Neuronal acetylcholine receptor; alpha4/beta2 as ChEMBL target CHEMBL1907589, mapped to UniProt P17787. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Neuronal acetylcholine receptor; alpha4/beta2 is the right protein anchor across sources, using UniProt P17787 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why nicotine dependence is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Neuronal acetylcholine receptor; alpha4/beta2 |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P17787 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Neuronal acetylcholine receptor subunit beta-2 |
| UniProt Accession | P17787 |
| Component Type | Protein |
| Sequence Length | 502 aa |
Neuronal acetylcholine receptor subunit beta-2
Review this target as Neuronal acetylcholine receptor; alpha4/beta2, mapped to UniProt P17787. ChEMBL maps the protein component as Neuronal acetylcholine receptor subunit beta-2. Sequence length is 502 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Neuronal acetylcholine receptor; alpha4/beta2 shows approved-linked disease relevance led by nicotine dependence. 5 more disease programs remain visible in the same review block.
Start review with nicotine dependence because it currently carries approved-linked support. Linked drugs include CYTISINICLINE, DIANICLINE, NICOTINE, NICOTINE POLACRILEX. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL6623 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL245243 | 10.74 | Ki | 0.018 | Preclinical |
| CHEMBL4168511 | 10.7 | Ki | 0.02 | Preclinical |
| CHEMBL6623 | 10.7 | EC50 | 0.02 | Preclinical |
| CHEMBL361465 | 10.68 | Ki | 0.021 | Preclinical |
| CHEMBL298517 | 10.59 | Ki | 0.026 | Preclinical |
| CHEMBL55716 | 10.57 | Ki | 0.027 | Preclinical |
| CHEMBL2164666 | 10.52 | Ki | 0.03 | Preclinical |
| CHEMBL298826 | 10.52 | Kd | 0.03 | Preclinical |
| CHEMBL3086984 | 10.51 | Ki | 0.031 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 266 | 713 | 7.0 |
| protein complex format | 139 | 127 | 7.5 |
| assay format | 9 | 76 | 8.0 |
| cell membrane format | 8 | 38 | 7.0 |
| single protein format | 3 | 20 | 6.9 |
| tissue-based format | 2 | 16 | 7.4 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 88 | 441 | 6.0 |
| assay format | 26 | 87 | 6.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 1 | 5.0 |